International Journal of Infectious Diseases最新文献

{"title":"Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: A systematic review and network meta-analysis.","authors":"Haiyue Wu, Lucia Li, Kun Fu, YuFei Shen, Yingnan Lu, Zexi Liao, Yingzhen Liu, Wenting Zha, Lisha Wu, Yu Zhang","doi":"10.1016/j.ijid.2024.107363","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107363","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy of 2-valent, 4-valent and 9-valent HPV vaccination in preventing persistent HPV infections and cervical intraepithelial neoplasia grade 2 or higher (CIN2+) lesions among women with different infection statuses at baseline.</p><p><strong>Methods: </strong>PubMed, Web of Science, Cochrane, Embase and ClinicalTrials.gov were searched from their inception to March 2024. Randomized controlled trials (RCTs) and post hoc analyses of RCTs reporting the risk of persistent HPV infections and CIN2+ among vaccinated women were included. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to summarize the intervention effects.</p><p><strong>Results: </strong>Eighteen RCTs and one post hoc analysis of RCTs were included. In the according-to-protocol (ATP) cohorts, the 4-valent vaccine was the most effective against HPV16/18-related persistent infections and CIN2+ (6-month persistent infections (6mPIs): OR 0.05, 95% CI [0.02, 0.15]; 12-month persistent infections (12mPIs): OR 0.02, 95% CI [0.00, 0.18]; CIN2+: OR 0.03 95% CI [0.01, 0.17]). For the total vaccination cohorts (TVCs), the 2-valent vaccine was most effective against HPV16/18-related 12mPIs and CIN2+ (12mPIs: OR 0.15, 95% CI [0.04, 0.63]; CIN2+: OR 0.52 95% CI [0.32, 0.87]), whereas the 4-valent vaccine was most effective against HPV16/18-related 6mPIs (OR 0.08, 95% CI [0.02, 0.28]).</p><p><strong>Conclusions: </strong>Vaccination against HPV can significantly reduce the risk of persistent HPV16/18-related infections and CIN2+, regardless of the HPV infection prevaccination. In addition to 4- and 9-valent vaccines, 2-valent vaccines could also provide satisfactory protection against persistent HPV16/18-related infections and CIN2+, especially over the long term, and may constitute an alternative for government-led vaccination programs in developing countries.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107363"},"PeriodicalIF":4.8,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marburg Virus Reaches Rwanda: How Close Are We to a Vaccine Solution?","authors":"Olivier Sibomana, Clyde Moono Hakayuwa, Jildas Munyantore","doi":"10.1016/j.ijid.2024.107371","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107371","url":null,"abstract":"<p><p>Marburg virus disease (MVD) is a highly virulent and often fatal disease caused by the Marburg virus, a member of the Filoviridae family, closely related to the Ebola virus. Historically, outbreaks have been sporadic but lethal across various African countries, with high case fatality rates (CFRs). In 2023, significant outbreaks occurred in Tanzania and Equatorial Guinea, with CFRs of 62.5% and 75%, respectively. In 2024, Rwanda faced its first outbreak, starting on September 27, 2024. By November 8, 2024, Rwanda had conducted 7,408 tests, confirming 66 cases, 15 of which were fatal, and 51 recoveries. Although no approved vaccine currently exists for MVD, global health authorities are prioritizing the development of effective vaccines. Drawing on insights from the rapid COVID-19 vaccine development, several promising candidates are under exploration, with the cAd3-MARV showing notable potential. This paper examines the current MVD outbreak in Rwanda and the progress toward developing a long-term vaccine solution.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107371"},"PeriodicalIF":4.8,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coinfection and Clinical Impact of Enterotoxigenic Escherichia coli Harboring Diverse Toxin Variants and Colonization Factors: 2017-2022.","authors":"Mohammad Ashraful Amin, Marjahan Akhtar, Zahid Hasan Khan, Md Taufiqul Islam, Md Golam Firoj, Yasmin Ara Begum, Sadia Isfat Ara Rahman, Mokibul Hassan Afrad, Taufiqur Rahman Bhuiyan, Fahima Chowdhury, A S G Faruque, Edward T Ryan, Firdausi Qadri, Ashraful Islam Khan","doi":"10.1016/j.ijid.2024.107365","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107365","url":null,"abstract":"<p><strong>Objectives: </strong>The severity of the diarrhea disease is exacerbated by co-infections that involve Enterotoxigenic Escherichia coli (ETEC) and other enteric pathogens, which complicate the diagnosis and treatment. This study explores the prevalence, clinical manifestations, and risk factors of ETEC and its co-infections in Dhaka, Bangladesh.</p><p><strong>Methods: </strong>The study used data from the Diarrheal Disease Surveillance System at Dhaka Hospital, involving 16,276 patients from 2017-2022. We identified 1404 ETEC-positive patients from the 16,276 data points to investigate the association between ETEC infections, co-infections, and clinical outcomes.</p><p><strong>Results: </strong>ETEC was identified in 1404 (8.6%) of cases, representing the most common infection among adults (56.6%). ETEC co-infection occurred combined with Vibrio cholerae (23%), Aeromonas (14.6%), rotavirus (11.8%), Campylobacter (6.5%), and Shigella spp. (1.7%), respectively. Adults were more likely to develop co-infections with ETEC and Vibrio cholerae, while children under five were more likely to develop ETEC co-infections with rotavirus. Co-infections with V. cholerae, rotavirus, and Salmonella spp. increased the likelihood of fever, while ETEC co-infections with V. cholerae increased risks of vomiting, dehydration, and intravenous fluids.</p><p><strong>Conclusions: </strong>ETEC and co-infections exacerbate illness severity and overburden healthcare systems. Policymakers should prioritize resilient healthcare strategies for ETEC and co-infections.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107365"},"PeriodicalIF":4.8,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicountry evaluation of the Xpert MTB/RIF assay for the diagnosis of intrathoracic tuberculosis in children using alternative specimens (nasopharyngeal aspirate and stool): A prospective cohort study conducted in Madagascar, Ivory Coast and Cameroon (TB Kids project).","authors":"Rindra Vatosoa Randremanana, Mathurin Tejiokem, Niaina Rakotosamimanana, Valérie Donkeng Donfack, Verlaine Bolyse Mbouchong, Mirella Randrianarisoa, Aina Harimanana, Jean Voisin Taguebue, Suzie Tetang Ndiang, Valère Itchy, Annick Robinson, Lovaniaina Ravelomanana, Mbola Rakotomahefa, Dina Ranoharison, Man-Koumba Soumahoro, Brigitte Gicquel, Raymond N'Guessan, Sara Eyangoh, Voahangy Rasolofo, Marius Irie Bi Irie, Anabelle Bai-Orsot, Jaudel Francis Yuya Septoh, Serge Abogo, Mamy Serge Raherison, Andrianantenaina Rakotoson, Vaomalala Raharimanga, Patrice Piola, Paulo Ranaivomanana, Jean-Marc Collard, Gabrielle Prisca Emmylou Andrianah, Turibio Razafindranaivo, Reziky Tiandraza Mangahasimbola, Kathleen Victoir","doi":"10.1016/j.ijid.2024.107366","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107366","url":null,"abstract":"<p><strong>Context: </strong>Tuberculosis (TB) diagnosis in children remains challenging due to the paucibacillary nature of specimens and the difficulty in obtaining suitable samples. The use of alternative samples like nasopharyngeal aspirate (NPA) and stools, alongside Xpert MTB/RIF testing, offers promising improvements.</p><p><strong>Objective: </strong>This study aimed to assess the diagnostic performance of the Xpert MTB/RIF test on NPA and stool samples for detecting intrathoracic TB in children from Madagascar, Cameroon, and Ivory Coast.</p><p><strong>Methods: </strong>Children under 15 years with suspected intrathoracic TB were enrolled in hospitals in these countries' capitals. Samples for analysis included standard specimens (gastric aspirate or sputum), NPA, stools, with additional HIV serology, TST tests, and chest X-rays. We used a composite reference standard to estimate the accuracy of the Xpert MTB/RIF test with alternative samples.</p><p><strong>Results: </strong>Of 1146 children analysed, the sensitivity of Xpert MTB/RIF was 58.3% for NPA and 45.5% for stool samples, with high specificity more than 95%. The diagnostic performance of Xpert MTB/RIF with alternative samples did not differ according to age group or to HIV status.</p><p><strong>Conclusion: </strong>The findings support the WHO's 2022 recommendation for using Xpert MTB/RIF with alternative samples in childhood TB diagnosis, underscoring its utility across different settings and HIV statuses.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107366"},"PeriodicalIF":4.8,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study.","authors":"Iván Martínez-Baz, Ana Navascués, Camino Trobajo-Sanmartín, Francisco Pozo, Miguel Fernández-Huerta, Maddi Olazabal-Arruiz, Lucía Argente-Colas, Guillermo Ezpeleta, Aitziber Echeverria, Itziar Casado, Carmen Ezpeleta, Jesús Castilla","doi":"10.1016/j.ijid.2024.107364","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107364","url":null,"abstract":"<p><strong>Objective: </strong>We estimated the influenza vaccination effectiveness (IVE) in preventing medical consultations and hospitalizations due to influenza during the 2023/24 season.</p><p><strong>Methods: </strong>Two test-negative case-control studies analyzed patients who consulted primary healthcare or were hospitalized for respiratory symptoms and were tested for influenza by PCR in the 2023/24 season in Navarre, Spain. Influenza vaccination status in the current and previous seasons was compared between confirmed influenza cases and test-negative controls. IVE was calculated as (1-adjusted odds ratio)x100.</p><p><strong>Results: </strong>Of 3133 hospitalized patients, 529 (17%) were positive for influenza: 71% A/H1N1, 23% A/H3N2, and 7% A non-subtyped. IVE to prevent hospitalizations was 43% (95%CI: 26-56%) overall, 61% (95%CI: 32-77%) in people younger than 65 years old and 35% (95%CI: 10-53%) in older people. IVE was 48% (95%CI: 30-61%) against influenza A/H1N1, and 15% (95%CI: -42-49%) against influenza A/H3N2. IVE in people vaccinated only in the previous season was 28% (95%CI: -5-51%). Among 417 outpatients, 146 (35%) were confirmed for influenza. IVE to prevent outpatient cases was 49% (95%CI: -9-76%) overall and 42% (95%CI: -33-74%) against influenza A/H1N1.</p><p><strong>Conclusions: </strong>IVE was moderate against influenza A/H1N1 and low against influenza A/H3N2 in the 2023/24 season.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107364"},"PeriodicalIF":4.8,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase III randomized controlled non-inferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) versus piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).","authors":"Junjie Li, Feng Wei, Peng Xiang, Zhengang Tang, Lianshu Ding, Luke Francis Chen, Maria Losada, Zlatka Iamboliyska, Fang Sun, Mingfen Zhu, Xiaodan Guo, Xiaoling Du, Chang Chen, Christopher Bruno, Sandra Koseoglu, Katherine Young, Min Zhou, Jieming Qu","doi":"10.1016/j.ijid.2024.107357","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107357","url":null,"abstract":"<p><strong>Objectives: </strong>Imipenem/cilastatin/relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor combination effective against gram-negative pathogens. Efficacy and safety of IMI/REL were studied in critically ill adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).</p><p><strong>Methods: </strong>In this phase III, double-blind, multinational, randomized trial (NCT03583333), adults with HABP/VABP were randomized 1:1 to receive intravenous IMI/REL (500 mg/250 mg) or piperacillin/tazobactam (PIP/TAZ; 4000 mg/500 mg) every 6 h for 7-14 days. The primary endpoint was 28-day all-cause mortality (ACM). Secondary endpoints were clinical response (CR), microbiological response (MR), and adverse event (AE) incidence.</p><p><strong>Results: </strong>In the modified intention-to-treat population (N = 270 [IMI/REL: n = 134; PIP/TAZ: n = 136]), demographics and baseline characteristics were comparable between treatment groups. Most patients were from China. IMI/REL was non-inferior to PIP/TAZ for 28-day ACM (11.2% vs 5.9%; adjusted difference [95% confidence interval]: 5.2% [-1.5 to 12.4]). Secondary outcomes were comparable between treatment groups, including favorable CR and MR. AEs resulting in death were generally consistent with pre-existing or underlying illness.</p><p><strong>Conclusions: </strong>IMI/REL met non-inferiority criteria versus PIP/TAZ for 28-day ACM, and safety profiles were comparable. This trial could support the use of IMI/REL to treat adults with HABP/VABP, including regional use in China.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107357"},"PeriodicalIF":4.8,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuberculosis Infection Prevalence and Treatment Completion among Refugees in the United States.","authors":"Dan Shen, Aurimar Ayala, Randall Reves, Michelle Haas, Renuka Khurana","doi":"10.1016/j.ijid.2024.107361","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107361","url":null,"abstract":"<p><strong>Background: </strong>Identifying and treating tuberculosis infection (TBI) among refugees at elevated risk for developing TB disease is crucial for TB prevention and elimination in the United States (U.S.). However, current evidence is limited by small sample sizes, inclusion of refugees from only a single country, and/or reliance solely on the tuberculin skin test (TST).</p><p><strong>Methods: </strong>Refugees in a large cohort study from ten U.S. sites underwent evaluation for TBI using three available tests: the TST and two interferon-gamma release assays (IGRAs). This study calculated TBI prevalence and assessed tuberculosis preventive treatment (TPT) completion among refugees, defining TBI prevalence as positive results on at least two tests.</p><p><strong>Results: </strong>Among 8960 refugees enrolled July 2012 through May 2017, TBI prevalence was 23.2% (95% confidence interval [CI]: 22.4%-24.1%). Completion of TPT was 81.2% (95% CI: 79.6%-82.7%). Shorter treatment regimens of 3-month were associated with higher treatment completion compared to regimens of 6-month or longer.</p><p><strong>Conclusions: </strong>The high TBI prevalence among refugees is a concern, but their high TPT acceptance and completion rates offer an opportunity. IGRA-based tests are preferred in this population; however, limited resources underscore the need for more precise screening approaches to better identify high-risk individuals who truly require TPT.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107361"},"PeriodicalIF":4.8,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fungal biomarkers in HIV-associated disseminated histoplasmosis: a multicenter diagnostic accuracy study on the Guiana shield.","authors":"Aurore Moussiegt, Sigrid Mac Donald, Marie Elisabeth Bougnoux, Marja Van Eer, Stephen Vreden, Tom Chiller, Diego H Caceres, Beatriz L Gomez, Mathieu Nacher, Olivier Lortholary, Antoine Adenis","doi":"10.1016/j.ijid.2024.107360","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107360","url":null,"abstract":"<p><strong>Background: </strong>Diagnosis of HIV-associated histoplasmosis remains challenging. Our objective was to compare the performances of (1→3)-β-D-Glucan (BDG) and Aspergillus galactomannan (GM) antigen for the diagnosis of HIV-associated histoplasmosis.</p><p><strong>Methods: </strong>We performed a diagnostic accuracy study using frozen primary serum specimens issued from consecutive hospitalized people living with HIV (PLWH) and blindly tested for BDG and GM using Fungitell® and PlateliaTM Aspergillus, respectively.</p><p><strong>Results: </strong>We included 121 sera with 92 HIV-associated histoplasmosis cases and 29 negative controls. At thresholds of 150 pg/mL and 0.5 for BDG and GM, sensitivity and specificity were respectively: 95% [85-100] vs 90% [77-100], 52% [34-70] vs 83% [69-97]. ROC curves showed AUCs of 0.82 [0.68-0.91] vs 0.92 [0.80-0.98] for BDG and GM, respectively. Post-test probabilities showed best performances at lowest thresholds for a negative testing of both BDG and GM, and at the 0.7 threshold for a positive GM test.</p><p><strong>Conclusion: </strong>If BDG alone may rule out histoplasmosis when negative, GM alone, either positive or negative, showed the best performances for the diagnosis of histoplasmosis. Given poorer performances of BDG and GM compared to Histoplasma antigen detection assays commercially available, they should be considered as an alternative in settings where Histoplasma antigen detection assays remain unavailable. However, this study essentially provides insights in the performances of fungal biomarkers in disseminated histoplasmosis and does not represent recommendations for best practices.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107360"},"PeriodicalIF":4.8,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to 'Impact of accumulative smoking exposure and chronic obstructive pulmonary disease on COVID-19 outcomes: report based on findings from the Japan COVID-19 task force' [IJID 128 (2023) 121-127].","authors":"Mayuko Watase, Katsunori Masaki, Shotaro Chubachi, Ho Namkoong, Hiromu Tanaka, Ho Lee, Takahiro Fukushima, Shiro Otake, Kensuke Nakagawara, Tatsuya Kusumoto, Takanori Asakura, Hirofumi Kamata, Makoto Ishii, Naoki Hasegawa, Yoshitaka Oyamada, Norihiro Harada, Tetsuya Ueda, Soichiro Ueda, Takashi Ishiguro, Ken Arimura, Fukuki Saito, Takashi Yoshiyama, Yasushi Nakano, Yoshikazu Mutoh, Yusuke Suzuki, Ryuya Edahiro, Hirohito Sano, Yasunori Sato, Yukinori Okada, Ryuji Koike, Yuko Kitagawa, Katsushi Tokunaga, Akinori Kimura, Seiya Imoto, Satoru Miyano, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga","doi":"10.1016/j.ijid.2024.107322","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107322","url":null,"abstract":"","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"107322"},"PeriodicalIF":4.8,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of bone destruction in patients with Talaromyces marneffei infection: A systematic review and meta-analysis.","authors":"Junhong Zhou, Deshuang Xi, Yilin Teng, Shaohui Zong, Gaofeng Zeng","doi":"10.1016/j.ijid.2024.107359","DOIUrl":"https://doi.org/10.1016/j.ijid.2024.107359","url":null,"abstract":"<p><strong>Objectives: </strong>This systematic review and meta-analysis aimed to evaluate the prevalence of bone destruction in patients with Talaromyces marneffei infection, examine distribution patterns of bone lesions, and assess differences between HIV-positive and HIV-negative patients.</p><p><strong>Methods: </strong>Following PRISMA guidelines, 15 studies involving 839 patients were analyzed. Random-effects meta-analysis was performed to estimate prevalence and odds ratios. Study quality was assessed using ROBINS-I.</p><p><strong>Results: </strong>The overall prevalence of bone destruction was 18% (95% CI: 10%-27%). HIV-negative patients showed significantly higher odds of bone destruction (OR: 0.09, 95% CI: 0.02-0.37). Bone lesions were widely distributed, with osseous involvement (45.7-71.4%) more prevalent than articular (7.1-66.7%). The skull, ribs, and lumbar vertebrae were commonly affected.</p><p><strong>Conclusions: </strong>Bone destruction is a significant complication in TM infection, particularly in HIV-negative patients. The diverse anatomical distribution emphasizes the need for comprehensive skeletal assessment in suspected cases.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107359"},"PeriodicalIF":4.8,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}